BACKGROUND: Previous studies have shown successful antitumor effects of systemically delivered double-deleted vaccinia virus (vvDD) against a number of adult tumor models, including glioma, colon and ovarian cancers. The purpose of this study was to investigate the oncolytic potential of vvDD against a panel of cell lines representative of pediatric solid tumors that are currently difficult to cure. METHODS: Cell lines derived from central nervous system atypical teratoid rhabdoid tumor (AT/RT) (BT12, BT16 and KCCF1), sarcoma (143B, HOS, RD and RH30), and neuroblastoma (SKNAS, SKNBE2, IMR-5 and IMR-32) were examined for vvDD mediated cytotoxicity defined by virus expansion followed by loss of tumor cell viability. The normal human fibroblast cell line HS68 was used as a control. Next, relevant orthotopic, subcutaneous and lung metastasis xenograft models were treated with intravenous doses of live vvDD or killed virus controls (DV). Tumor growth inhibition and viral replication were quantified and survival outcomes of these animals were assessed. RESULTS: vvDD was able to infect and kill nine of eleven of the pediatric tumor cells (81.8%) in vitro. In xenograft models, intravenous administration of a single dose of vvDD significantly inhibited the growth of tumors and prolonged the survival of intracranial and metastatic tumors. CONCLUSIONS: Oncolytic vvDD administered i.v. shows activity in preclinical models of pediatric malignancies that are resistant to many currently available treatments. Our data support further evaluation of vvDD virotherapy for refractory pediatric solid tumors.
BACKGROUND: Previous studies have shown successful antitumor effects of systemically delivered double-deleted vaccinia virus (vvDD) against a number of adult tumor models, including glioma, colon and ovarian cancers. The purpose of this study was to investigate the oncolytic potential of vvDD against a panel of cell lines representative of pediatric solid tumors that are currently difficult to cure. METHODS: Cell lines derived from central nervous system atypical teratoid rhabdoid tumor (AT/RT) (BT12, BT16 and KCCF1), sarcoma (143B, HOS, RD and RH30), and neuroblastoma (SKNAS, SKNBE2, IMR-5 and IMR-32) were examined for vvDD mediated cytotoxicity defined by virus expansion followed by loss of tumor cell viability. The normal human fibroblast cell line HS68 was used as a control. Next, relevant orthotopic, subcutaneous and lung metastasis xenograft models were treated with intravenous doses of live vvDD or killed virus controls (DV). Tumor growth inhibition and viral replication were quantified and survival outcomes of these animals were assessed. RESULTS: vvDD was able to infect and kill nine of eleven of the pediatric tumor cells (81.8%) in vitro. In xenograft models, intravenous administration of a single dose of vvDD significantly inhibited the growth of tumors and prolonged the survival of intracranial and metastatic tumors. CONCLUSIONS: Oncolytic vvDD administered i.v. shows activity in preclinical models of pediatric malignancies that are resistant to many currently available treatments. Our data support further evaluation of vvDD virotherapy for refractory pediatric solid tumors.
Authors: Caroline J Breitbach; James Burke; Derek Jonker; Joe Stephenson; Andrew R Haas; Laura Q M Chow; Jorge Nieva; Tae-Ho Hwang; Anne Moon; Richard Patt; Adina Pelusio; Fabrice Le Boeuf; Joe Burns; Laura Evgin; Naomi De Silva; Sara Cvancic; Terri Robertson; Ji-Eun Je; Yeon-Sook Lee; Kelley Parato; Jean-Simon Diallo; Aaron Fenster; Manijeh Daneshmand; John C Bell; David H Kirn Journal: Nature Date: 2011-08-31 Impact factor: 49.962
Authors: Hue H Luu; Quan Kang; Jong Kyung Park; Weike Si; Qing Luo; Wei Jiang; Hong Yin; Anthony G Montag; Michael A Simon; Terrance D Peabody; Rex C Haydon; Carrie W Rinker-Schaeffer; Tong-Chuan He Journal: Clin Exp Metastasis Date: 2005 Impact factor: 5.150
Authors: Xue Qing Lun; Ji-Hyun Jang; Nan Tang; Helen Deng; Renee Head; John C Bell; David F Stojdl; Catherine L Nutt; Donna L Senger; Peter A Forsyth; J Andrea McCart Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531
Authors: Karsten Geletneky; Johannes Huesing; Jean Rommelaere; Joerg R Schlehofer; Barbara Leuchs; Michael Dahm; Ottheinz Krebs; Magnus von Knebel Doeberitz; Bernard Huber; Jacek Hajda Journal: BMC Cancer Date: 2012-03-21 Impact factor: 4.430
Authors: XueQing Lun; Jennifer Chan; Hongyuan Zhou; Beichen Sun; John J P Kelly; Owen Owen Stechishin; John C Bell; Kelley Parato; Kang Hu; Dominique Vaillant; Jiahu Wang; Ta-Chiang Liu; Caroline Breitbach; David Kirn; Donna L Senger; Peter A Forsyth Journal: Mol Ther Date: 2010-08-31 Impact factor: 11.454
Authors: Adam W Studebaker; Brian Hutzen; Christopher R Pierson; Terri A Shaffer; Corey Raffel; Eric M Jackson Journal: Neuro Oncol Date: 2015-04-02 Impact factor: 12.300
Authors: Bingtao Tang; Zong Sheng Guo; David L Bartlett; David Z Yan; Claire P Schane; Diana L Thomas; Jia Liu; Grant McFadden; Joanna L Shisler; Edward J Roy Journal: Clin Cancer Res Date: 2020-02-04 Impact factor: 12.531
Authors: Yu-Ping Liu; Jiahu Wang; Victoria A Avanzato; Jamie N Bakkum-Gamez; Stephen J Russell; John C Bell; Kah-Whye Peng Journal: Gynecol Oncol Date: 2014-01-14 Impact factor: 5.482
Authors: Wesley A Grimm; Jeannette S Messer; Stephen F Murphy; Thomas Nero; James P Lodolce; Christopher R Weber; Mark F Logsdon; Sarah Bartulis; Brooke E Sylvester; Amanda Springer; Urszula Dougherty; Timothy B Niewold; Sonia S Kupfer; Nathan Ellis; Dezheng Huo; Marc Bissonnette; David L Boone Journal: Gut Date: 2015-02-02 Impact factor: 23.059